Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: J Autoimmun. 2019 Aug 2;106:102306. doi: 10.1016/j.jaut.2019.102306

Figure 1.

Figure 1.

Patients demonstrate HLA and epitope specific tetramer recognition by CD4+ T cells. (A) Amino acid sequence alignment of mouse MPO409–428 (grey), human MPO435–454, and human MPO447–461. Amino acid differences between mouse and human epitopes in red. (B) Gating strategy for tetramer+CD4+ T cells with no tetramer control, MPO447–461 scramble control, and HLA-DRB4 MPO435–454. Tetramer positivity for each individual was based on the corresponding no-tetramer control. (C-D) CD4+ T cell recognition of tetramers in MPO-ANCA patients (n=27; black dots) and HLA-matched healthy controls (n=6; gray dots). Some patients and healthy controls had both HLAs and were used in both studies while some samples were only used for one HLA. Dashed red line indicates threshold of positivity determined by the average plus two standard deviations of patient and healthy control MPO447–461scramble tetramer positivity. (C) HLA-DPB1*04:01 tetramer carrying MPO peptides (D) HLA-DRB4*01:01 tetramers carrying MPO peptides. P values were calculated by paired signed rank test.